Skip to main content
SpringerLink
Log in

Zwei Fliegen mit einer Klatsche

SGLT2-Antagonisten – ein Medikament gegen Diabetes und Bluthochdruck?

  • Fortbildung
  • Published:
CardioVasc Aims and scope

SGLT2-Inhibitoren sind wirksam in der Behandlung von Diabetes mellitus und haben gleichzeitig eine geringfügig blutdrucksenkende Wirkung. Welche Mechanismen diesem Zusammenhang zugrundeliegen und weshalb diese Substanzen gerade für hypertone Diabetiker interessant sein könnten, wird in der folgenden Übersicht herausgestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Sowers JR, Epstein M and Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–9

    Article  CAS  PubMed  Google Scholar 

  2. Rahmouni K, Correia ML, Haynes WG and Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9–14

    Article  CAS  PubMed  Google Scholar 

  3. Ehrenkranz JR, Lewis NG, Kahn CR and Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–8

    Article  CAS  PubMed  Google Scholar 

  4. Baker WL, Smyth LR, Riche DM et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–75.e9

    Article  CAS  PubMed  Google Scholar 

  5. Solini A. Extra-glycaemic properties of empagliflozin. Diabetes Metab Res Rev. 2015. doi: 10.1002/dmrr.2666

    Google Scholar 

  6. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74

    Article  PubMed  Google Scholar 

  7. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kim GRM, Andersen KR, Zeller C et al. Effect of empagliflozin compared with glimepiride as add-on to metformin for 2 years on the amount and distribution of body fat in patients with type 2 diabetes. Diabetologia 2014;75(Suppl. 1):330, 818.

    Google Scholar 

  9. Ferrannini G, Hach T, Crowe S et al. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38:1730–5

    Article  PubMed  Google Scholar 

  10. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97

    Article  CAS  PubMed  Google Scholar 

  11. Fu YGM, Mayoux E, Masuda T, Vallon V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 2014;63(Suppl. 1):512–P

    Google Scholar 

  12. Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. American journal of physiology. Ren Physiol. 2015;308:F1343–57

    Article  CAS  Google Scholar 

  13. Bailey CJ, Gross JL, Hennicken D et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC med. 2013;11:43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Davies MJ, Trujillo A, Vijapurkar U et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426–9

    Article  CAS  PubMed  Google Scholar 

  15. Ferrannini E, Berk A, Hantel S et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Feig DI. The role of uric acid in the pathogenesis of hypertension in the young. J Clin Hypertens. 2012;14:346–52

    Article  CAS  Google Scholar 

  17. Soletsky B and Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60:1148–56

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Nephrologie und Tranplantationsmedizin, Hypertoniezentrum, Hindenburgdamm 30, 12203, Berlin, Deutschland

    Alexander Reshetnik

  2. http://www.springermedizin.de

    Christopher Gohlisch & Markus van der Giet

Authors
  1. Alexander Reshetnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher Gohlisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus van der Giet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Reshetnik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reshetnik, A., Gohlisch, C. & van der Giet, M. SGLT2-Antagonisten – ein Medikament gegen Diabetes und Bluthochdruck?. CV 16, 42–44 (2016). https://doi.org/10.1007/s15027-016-0819-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-016-0819-9

Search

Navigation